Compare JAZZ & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | BAX |
|---|---|---|
| Founded | 2003 | 1931 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 13.9B |
| IPO Year | 2007 | 1994 |
| Metric | JAZZ | BAX |
|---|---|---|
| Price | $246.94 | $26.41 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 9 |
| Target Price | ★ $217.57 | $21.00 |
| AVG Volume (30 Days) | 706.8K | ★ 7.7M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.17 | 0.21 |
| Revenue | $1,618,693,000.00 | ★ $11,244,000,000.00 |
| Revenue This Year | $6.22 | $1.96 |
| Revenue Next Year | $7.68 | $2.22 |
| P/E Ratio | ★ $35.17 | $126.86 |
| Revenue Growth | N/A | ★ 5.72 |
| 52 Week Low | $121.40 | $15.73 |
| 52 Week High | $265.05 | $30.00 |
| Indicator | JAZZ | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 56.47 |
| Support Level | $222.49 | $18.74 |
| Resistance Level | $250.49 | $30.00 |
| Average True Range (ATR) | 7.43 | 0.89 |
| MACD | -1.30 | -0.28 |
| Stochastic Oscillator | 26.05 | 22.29 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.